Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 21514447)


Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.

Arbini AA, Greco M, Yao JL, Bourne P, Marra E, Hsieh JT, di Sant'agnese PA, Moro L.

Am J Pathol. 2011 May;178(5):2367-76. doi: 10.1016/j.ajpath.2011.01.050.


Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.

Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW.

Clin Cancer Res. 2002 Nov;8(11):3419-26.


Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells.

Shibahara T, Onishi T, Franco OE, Arima K, Sugimura Y.

Anticancer Res. 2005 May-Jun;25(3B):1881-8.


Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.

Li B, Lu W, Yang Q, Yu X, Matusik RJ, Chen Z.

Prostate. 2014 Apr;74(4):421-32. doi: 10.1002/pros.22763. Epub 2013 Dec 17.


Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells.

Jiang J, Pan Y, Regan KM, Wu C, Zhang X, Tindall DJ, Huang H.

Prostate. 2012 Feb 1;72(2):225-32. doi: 10.1002/pros.21430. Epub 2011 May 31.


[Correlation of Skp2 and P27kip1 protein expression and clinicopathological features of prostate cancer].

Zheng XY, Ding W, Xie LP, Chen ZD.

Ai Zheng. 2004 Feb;23(2):215-8. Chinese.


Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate.

Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C, Zhang H.

Cancer Res. 2003 Apr 1;63(7):1583-8.


Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation.

Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, Takata T.

Mol Cancer Ther. 2005 Mar;4(3):471-6.


Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.

Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara J, Perez-Soler R, Cordon-Cardo C, Pagano M, Osman I.

Clin Cancer Res. 2003 Jul;9(7):2613-9.


Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation.

Moro L, Arbini AA, Marra E, Greco M.

J Biol Chem. 2005 Jun 10;280(23):22482-91. Epub 2005 Apr 1. Retraction in: J Biol Chem. 2014 Jun 20;289(25):17423.


The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.

Lu L, Schulz H, Wolf DA.

BMC Cell Biol. 2002 Aug 20;3:22. Epub 2002 Aug 20.


Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9.

Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M.

Cancer Sci. 2008 Mar;99(3):553-63. doi: 10.1111/j.1349-7006.2007.00719.x. Epub 2007 Dec 27. Erratum in: Cancer Sci. 2014 Jul;105(7):932.


High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.

Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators, Fox S, Thorne H.

BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.


Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer.

Ben-Izhak O, Lahav-Baratz S, Meretyk S, Ben-Eliezer S, Sabo E, Dirnfeld M, Cohen S, Ciechanover A.

J Urol. 2003 Jul;170(1):241-5.


Periostin: a promising target of therapeutical intervention for prostate cancer.

Sun C, Zhao X, Xu K, Gong J, Liu W, Ding W, Gou Y, Xia G, Ding Q.

J Transl Med. 2011 Jun 30;9:99. doi: 10.1186/1479-5876-9-99.


Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A.

PLoS Genet. 2010 Jun 24;6(6):e1000995. doi: 10.1371/journal.pgen.1000995.


Skp2 is oncogenic and overexpressed in human cancers.

Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W.

Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5043-8. Epub 2001 Apr 17.


Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.

Moro L, Arbini AA, Marra E, Greco M.

Int J Oncol. 2007 Jan;30(1):217-24.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk